What Alumis does

Alumis Inc. is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California, developing targeted therapies for immune-mediated diseases. The company is publicly traded on NASDAQ under the ticker ALMS following a January 2026 upsized offering that raised approximately $345.1M, and it operates a portfolio of three core clinical-stage assets: envudeucitinib (ESK-001), a next-generation allosteric oral TYK2 inhibitor designed for maximal 24-hour inhibition of IL-23/IL-17 and type I interferon signaling; A-005, a brain-penetrant allosteric TYK2 inhibitor targeting neuroinflammatory and neurodegenerative diseases; and lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease acquired through the February 2025 merger with ACELYRIN. Underlying the pipeline is a proprietary data analytics platform that integrates multi-omic and clinical data to identify targets, indications, and patient segments, with the company stating the platform identified approximately 20 diseases impacted by TYK2.

Alumis' lead clinical catalyst is the Phase 3 ONWARD1 and ONWARD2 program in moderate-to-severe plaque psoriasis, where envudeucitinib achieved a 68% PASI 90 response rate and 41% PASI 100 (complete clearance) at Week 24 across 1,771 enrolled patients, outperforming the typical 50–55% benchmark for oral TYK2 inhibitors. The program is positioned for NDA submission in H2 2026, with a parallel Phase 2b LUMUS study in systemic lupus erythematosus toplining in Q3 2026 and a Phase 2 study of A-005 in multiple sclerosis planned for H1 2026. The pipeline also includes undisclosed programs targeting IRF5 and additional targets, all developed using the company's precision-medicine framework.

The business model is pre-commercial: Alumis generates no meaningful product revenue and reported approximately $1.93M in Q4 2025 from licensing/collaboration activities. The company employs 101–250 staff and is building a specialty pharmaceutical commercial organization, including a Chief Commercial Officer hired from Amgen/Horizon Therapeutics in 2025 with experience launching TEPEZZA. Future revenue is expected to come from U.S. specialty pharmacy distribution of envudeucitinib, lonigutamab, and A-005, supplemented by the Kaken Pharmaceutical co-commercialization arrangement in Japan and additional regional licensing deals. As of early 2026 the company held approximately $569.5M in cash against a $93.1M quarterly burn, providing runway into Q4 2027.

Name

Alumis

Legal name

Alumis Inc.

Website

https://alumis.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Alumis is a clinical-stage biopharmaceutical company developing next-generation oral TYK2 inhibitors and a subcutaneous anti-IGF-1R antibody for immune-mediated diseases including plaque psoriasis, systemic lupus erythematosus, thyroid eye disease, and neuroinflammatory conditions.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Specialty Therapeutics for Immune-Mediated Diseases

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Tyrosine kinase inhibitors
• Autoimmune disease therapies
• Monoclonal antibody therapeutics
• Immune-mediated disease treatments
• Precision medicine biopharmaceuticals

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company expecting to generate revenue through commercial sales of envudeucitinib and other pipeline products upon FDA approval. Revenue will come from prescription drug sales targeting immune-mediated diseases, distributed through specialty pharmacy channels.
2. Licensing and Strategic Partnerships: Company has retained global rights for all programs except envudeucitinib plaque psoriasis rights shared with Kaken in Japan. This creates potential licensing revenue streams from co-development and co-commercialization arrangements in specific geographic markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. Its core offerings are three clinical-stage drug candidates: envudeucitinib (an oral allosteric TYK2 inhibitor for plaque psoriasis, SLE, and neuroinflammatory conditions), lonigutamab (a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease), and A-005 (a brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis, Alzheimer's, and Parkinson's). The company is preparing for first commercial launches upon FDA approval and will distribute through specialty pharmacy channels.

Product overview

Alumis is a clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation targeted therapies for immune-mediated diseases. The company's pipeline consists of three core clinical programs: Envudeucitinib (ESK-001), an oral TYK2 inhibitor in Phase 3 for plaque psoriasis and Phase 2b for systemic lupus erythematosus; Lonigutamab, a subcutaneous anti-IGF-1R monoclonal antibody for thyroid eye disease (acquired through merger with Acelyrin); and A-005, a brain-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company also maintains undisclosed programs targeting IRF5 and additional targets. Alumis leverages a proprietary data analytics platform to drive precision medicine development.

Differentiator

Problem solved

Functional benefit

Products and services

• Envudeucitinib (ESK-001) A next-generation, highly selective oral allosteric TYK2 inhibitor precision-engineered for maximal 24-hour inhibition to correct immune dysregulation in IL-23/IL-17 driven diseases including plaque psoriasis, systemic lupus erythematosus, and neuroinflammatory conditions. Phase 3 in plaque psoriasis and Phase 2 in SLE.
• Lonigutamab A next-generation anti-insulin-like growth factor 1 receptor (anti-IGF-1R) humanized IgG1 monoclonal antibody designed for subcutaneous delivery for thyroid eye disease, with novel epitope binding that triggers rapid receptor internalization and degradation. First subcutaneous anti-IGF-1R therapy to demonstrate efficacy in TED comparable to IV-administered treatments.
• A-005 The first allosteric TYK2 inhibitor with demonstrated ability to cross the human blood-brain barrier, designed for neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Enables targeted treatment within the CNS and periphery.

Quantifiable outcome

• 68% PASI 90 response rate at Week 24 in Phase 3 ONWARD1 trial for plaque psoriasis
• +5 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and regional.

• ACELYRINcoreStrategic or Co-development Partner · 6 February 2025Merger agreement announced February 2025 creating a late-stage clinical biopharma company. All-stock transaction with Alumis owning approximately 55% of the combined entity. Combined pipeline included Alumis' ESK-001 and ACELYRIN's lonigutamab. Pro forma cash position of approximately $737 million. Expected to close Q2 2025.
• Kaken PharmaceuticalregionalChannel Partner/ Reseller/ DistributorCo-commercialization partner for envudeucitinib in plaque psoriasis in Japan. Alumis retains global rights for all other territories and indications including SLE and other potential indications.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bristol Myers Squibb: Markets Sotyktu (deucravacitinib), the first and currently only approved oral allosteric TYK2 inhibitor for plaque psoriasis. Directly competes with envudeucitinib in the same indication and class, and also has major psoriasis/autoimmune franchises (Zeposia, Otezla).
• Pfizer: Developing litfilo (abrocitinib/next-gen oral TYK2 candidate) and markets Xeljanz (tofacitinib) and Cibinqo in autoimmune disease. Direct competitor in the oral TYK2 / JAK inhibitor class for psoriasis and broader autoimmune indications.

Broad incumbents

• AbbVie: Markets Skyrizi (risankizumab) and Rinvoq (upadacitinib), which dominate moderate-to-severe plaque psoriasis and other autoimmune indications (psoriatic arthritis, Crohn's, atopic dermatitis). Sets the efficacy and formulary benchmark that envudeucitinib must compete against at launch.
• Eli Lilly: Markets Taltz (ixekizumab) in plaque psoriasis and psoriatic arthritis, and Olumiant (baricitinib) in autoimmune indications. A major incumbent in the immunology space with deep commercial infrastructure that any new oral entrant must contend with.
• Amgen: Acquired Horizon Therapeutics in 2023, gaining TEPEZZA — the leading anti-IGF-1R therapy for thyroid eye disease. Directly competes with Alumis's lonigutamab in TED and has deep rare disease commercial infrastructure overlapping with Alumis's planned specialty pharmacy approach.
• Sanofi: Markets Dupixent (dupilumab), a leading injectable across atopic dermatitis, asthma and other type 2 inflammatory conditions, and previously acquired Principia Biopharma — Alumis's leadership team's prior company. Represents both a major competitor and a potential strategic acquirer.
• Takeda Pharmaceutical: Global pharmaceutical company with a major immunology franchise (Entyvio for IBD) and active development in lupus and other autoimmune indications. Claire Langrish (Alumis SVP Immunology) previously held positions at Takeda, and the company represents a relevant partner/competitor for cross-indication autoimmune programs.

Emerging players

• Arcutis Biotherapeutics: Specialty dermatology company marketing Zoryve (roflumilast) topical cream and foam for psoriasis, atopic dermatitis and seborrheic dermatitis. An emerging oral/topical dermatology competitor targeting the same moderate plaque psoriasis prescriber base as Alumis.
• UCB: Specialty immunology company marketing Rystiggo (rozanolixizumab) and Zilbrysq for autoimmune neurology, and Cimzia/Evenity in other immune indications. Comparable mid-to-large specialty pharma model focused on autoimmune disease launches.
• Ventyx Biosciences: Clinical-stage immunology company developing oral TYK2 and other kinase inhibitors for psoriasis and other autoimmune indications. Direct competitor in the oral kinase space and former employer of Alumis's CMO, Dr. Jörn Drappa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/EskerTx
• LinkedInlinkedin.com/company/esker-therapeutics
• Facebookfacebook.com/alumniglobalsearch

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alumis